Zacks Investment Research upgraded shares of NPS PHARMA INC (NPSP) from NEUTRAL to OUTPERFORM on July 12, 2013, with a target price of $18.30.
NPS PHARMACEUTICALS INC. is engaged in the discovery and development of orally active, small molecule drugs that target surface receptors and ion channels. Company is also applying its calcium receptor technology to the development of orally active, small molecule drugs which have neuroprotectant properties and target certain calcium channels in order to provide treatments for stoke, head trauma, chronic pain and epilepsy.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on NPS PHARMA INC (NPSP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment